Prakash C, Soliman V
Department of Drug Metabolism, Central Research Division, Pfizer Inc.
Drug Metab Dispos. 1997 Nov;25(11):1288-97.
The absorption and metabolism of a novel antianxiety drug candidate, CP-93,393, ((7S, 9aS)-2-(pyrimidin-2-yl)-7-(succinimidomethyl)-octahydro-1H-p yrido[1, 2-a]pyrazine) were investigated in bile-cannulated Long Evans rats after oral administration of a single 30 mg/kg base equivalent dose of 14C-CP-93,393 (HCl salt). Urine, bile, plasma, and feces were collected and assayed for total radioactivity. Plasma samples were also analyzed for unchanged drug using an LC/MS/MS assay. Metabolic profiles of 14C-CP-93,393 were obtained in urine, bile, and plasma. Structural characterization of metabolites was carried out by LC/MS using a combination of full scan, product ion, constant neutral loss, and multiple reaction ion monitoring techniques. CP-93,393 was completely absorbed, as less than 1% of the administered radioactivity was recovered in the feces. The major portion of the radioactivity was recovered in bile, suggesting that the biliary route was the primary route of excretion. Total recovery of administered dose was 97.4 +/- 3.3% from male rats and 85.3 +/- 9.6% from female rats. Approximately 32% of the administered radioactive dose was recovered in urine of female rats, while only 20% was recovered in urine of male rats. In contrast, biliary recoveries of the radioactivity were higher for male rats (approximately 77% for males and 53% for females). Mean Cmax values for the unchanged CP-93, 393 and total radioactivity were significantly higher in the female rats than in the male rats. Similarly, mean AUC(0-t) values for the unchanged drug and radioactivity were also higher in female rats. These findings suggested that CP-93,393 was eliminated more rapidly in the male rats than in the female rats. CP-93,393 and a total of 16 metabolites were identified in urine, bile, and plasma. Based on the structures of oxidative metabolites, four metabolic pathways of CP-93,393 were identified: hydroxylation at the pyrimidine ring, hydroxylation at the succinimide ring, hydroxylation alpha to the nitrogen of the piperazine ring, and hydrolysis of amide bond of the succinimide ring. The major oxidative metabolites were excreted as sulfate and/or glucuronide conjugates. The structures of regioisomeric glucuronides were established by a novel tandem mass spectrometric technique. The glucuronides were dissociated at the orifice, and the resulting aglycones were then analyzed by MS/MS studies. The identified metabolites accounted for >90% of the total radioactivity present in urine, bile, and plasma.
在给胆管插管的Long Evans大鼠口服单剂量30 mg/kg碱基当量的14C-CP-93,393(盐酸盐)后,对一种新型抗焦虑候选药物CP-93,393((7S, 9aS)-2-(嘧啶-2-基)-7-(琥珀酰亚胺甲基)-八氢-1H-吡啶并[1, 2-a]吡嗪)的吸收和代谢情况进行了研究。收集尿液、胆汁、血浆和粪便并测定总放射性。还使用液相色谱/串联质谱分析法对血浆样品中的原形药物进行分析。获得了14C-CP-93,393在尿液、胆汁和血浆中的代谢谱。通过液相色谱/质谱联用技术,结合全扫描、产物离子、恒定中性丢失和多反应离子监测技术,对代谢物进行结构表征。CP-93,393被完全吸收,因为粪便中回收的给药放射性不到1%。大部分放射性在胆汁中回收,表明胆汁途径是主要排泄途径。雄性大鼠给药剂量的总回收率为97.4±3.3%,雌性大鼠为85.3±9.6%。雌性大鼠尿液中回收了约32%的给药放射性剂量,而雄性大鼠尿液中仅回收了20%。相比之下,雄性大鼠胆汁中放射性的回收率更高(雄性约为77%,雌性约为53%)。雌性大鼠中CP-93,393原形和总放射性的平均Cmax值显著高于雄性大鼠。同样,雌性大鼠中原形药物和放射性的平均AUC(0-t)值也更高。这些结果表明,CP-93,393在雄性大鼠中的消除速度比雌性大鼠更快。在尿液、胆汁和血浆中鉴定出CP-93,393以及总共16种代谢物。根据氧化代谢物的结构,确定了CP-93,393的四条代谢途径:嘧啶环羟基化、琥珀酰亚胺环羟基化、哌嗪环氮原子α位羟基化以及琥珀酰亚胺环酰胺键水解。主要的氧化代谢物以硫酸盐和/或葡萄糖醛酸结合物的形式排泄。通过一种新型串联质谱技术确定了区域异构体葡萄糖醛酸苷的结构。葡萄糖醛酸苷在孔口处解离,然后通过串联质谱研究对产生的苷元进行分析。鉴定出的代谢物占尿液、胆汁和血浆中总放射性的90%以上。